News & Updates

Drinking coffee and tea, separately or in combination, seems to help protect against the risk of stroke or dementia, according to a recent study.

Working out can bring relief to patients with primary headaches, with aerobic and strength training beneficial in migraine or tension-type headache (TTH), respectively, according to the results of a meta-analysis.

Patients with hyperlipidemia who take their statin medication as prescribed appear to do well, with treatment adherence conferring significant protection against the risk of ischaemic and haemorrhagic strokes, as reported in a study.

Most patients with traumatic brain injury receive delayed prophylaxis, with no association seen between incidence of venous thromboembolism (VTE) and prophylaxis regimen, suggests a study. However, a significant difference is observed in VTE incidence stratified by time to prophylaxis.

Short-term treatment with zolpidem or zopiclone in older patients with Alzheimer’s disease and insomnia appears beneficial, even though safety and tolerance issues have yet to be personalized in healthcare settings and further investigated in subsequent trials, according to a study.

Mild-to-moderate COVID-19 during pregnancy does not appear to affect the foetal brain, according to a prospective study presented at RSNA 2021.

Patients on older antiplatelet or anticoagulant agents who sustain head trauma may be at an increased risk of delayed post-traumatic intracranial haemorrhage (ICH) than those on direct oral anticoagulants (DOACs), according to a retrospective study presented at RSNA 2021.

In individuals who had been on antidepressant therapy for at least 9 months but felt well enough to consider discontinuing, the risk of relapse of depression was greater among those who stopped vs those who carried on with their current regimen, the ANTLER* trial has shown.

In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.